Chiasma, Inc. is a biopharmaceutical company in the advanced stages of clinical development, specializing in oral drug formulations. The company utilizes its Transient Permeability Enhancer (TPE) technology platform to develop treatments for rare and serious chronic conditions on a global scale. A key product in its pipeline is MYCAPSSA, an oral octreotide capsule currently in Phase III clinical trials. MYCAPSSA is intended for adult patients diagnosed with acromegaly, a disorder marked by the overproduction of growth hormone in the body. Founded in 2001, Chiasma, Inc. is headquartered in Needham, Massachusetts.


Net sales
Gross margin
Net income